Introduction
============

Stroke is a medical emergency, with a mortality rate higher than most forms of cancer. It is the second leading cause of death in developed countries ([@b1]) and is the most common cause of serious, long-term disability in adults ([@b2]). In addition to the impact on patients and families, there are major economic consequences ([@b2], [@b3]): the total cost of stroke in the USA is estimated to exceed US \$56 billion in 2005 ([@b4]). In addition, the incidence of stroke is increasing with the ageing of populations and is therefore a major challenge to health planners ([@b5]).

Important evidence-based advances in acute stroke have included proof of the benefit of organised care in stroke units, modern brain imaging, thrombolytic therapy, the modest benefit of acute aspirin in ischaemic stroke and the potential use of haemostatic therapy with recombinant factor VIIa (rFVIIa) in intracerebral haemorrhage (ICH). Currently, intravenous recombinant tissue plasminogen activator (rt-PA) is the only pharmacological treatment licensed for treatment of acute ischaemic stroke in most Western countries, but the uptake of rt-PA has been disappointingly low, and \>95% of patients with ischaemic stroke do not receive any specific pharmacological therapy ([@b6]--[@b9]). Of particular concern is that, while ≤15% of ischaemic stroke patients receive rt-PA in some well-organised stroke centres ([@b8]), \<2--3% of patients receive such treatment in community hospitals ([@b7]). Why are the majority of ischaemic stroke patients unable to access acute therapy? Clearly, a lack of awareness of the common symptoms of stroke remains a major educational challenge, and the urgency of stroke treatment is still poorly appreciated. Despite the proven benefit of stroke units, the majority of patients in most countries cannot access specialised stroke care. In this paper, we review current treatment guidelines and new therapeutic prospects, emphasising the importance of early intervention and the need for a multidisciplinary approach to the management of stroke patients.

Pathophysiology of Acute Stroke Poses an Emergency
==================================================

The two main developments underlying therapeutic advances in stroke are the delineation of the ischaemic penumbra in ischaemic stroke and the observation of haematoma growth in ICH.

Ischaemic Stroke
----------------

The severity of an acute ischaemic stroke depends on the degree of impairment of cerebral blood flow and the time to reperfusion. As the ischaemic process evolves, most commonly due to thromboembolic arterial occlusion, there is a progressive decrease in cerebral blood flow. When this falls from normal levels of approximately 50 to \<10 ml/100 g/min, neuronal cell death rapidly occurs. However, between the ischaemic core and the normally perfused brain at the periphery lies the ischaemic penumbra, a zone of moderately reduced cerebral blood flow, dependent on the proximal arterial occlusion and collateral supply ([Fig. 1](#fig1){ref-type="fig"}). Within the ischaemic penumbra, the neurones are hypoxic, functionally inactive, but still viable, and this is the region targeted by acute stroke therapies. The penumbra is a dynamic, time-based region in which brain tissue will undergo necrosis over hours to days due to perfusion failure and a secondary cascade of damaging biochemical events.

![Patient with an acute right middle cerebral territory infarct, demonstrating a large ischaemic penumbra perfusion-weighted imaging (PWI) (perfusion lesion) \> diffusion-weighted imaging (DWI) (diffusion lesion). The magnetic resonance angiogram (MRA) shows an occluded right middle cerebral artery. The penumbra represents threatened tissue, which is a target for acute stroke therapies such as thrombolysis](ijcp_873_f1){#fig1}

These neurotoxic processes include release of glutamate, activation of *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) and other cell receptors, influx of sodium and calcium into cells, release of free-radical species and, ultimately, cellular destruction. The critical time for effective reperfusion, based on magnetic resonance-imaging studies, may be around 4.5 h, with earlier restoration leading to greater tissue salvage ([@b10]). However, the therapeutic time windows in ischaemia remain uncertain. Later, pathophysiological processes include inflammatory reactions and free-radical release ([@b11]). A limited therapeutic window of opportunity underlies the concept that 'time is brain', and current approaches to therapy are aimed at limiting stroke damage and improving functional outcomes.

ICH
---

More recent studies have shown that ICH is also a dynamic process and potentially amenable to therapeutic intervention. A prospective study in ICH showed that 38% of patients exhibited substantial haematoma growth (greater than one-third increase in volume) if imaged with computerised tomography (CT) within 3 h of onset of stroke and repeated 24 h later ([@b12]) ([Fig. 2](#fig2){ref-type="fig"}). Most of this growth (26%) occurred within 1 h of the first scan. This expansion is probably due to continued bleeding or re-bleeding. This observation led to the hypothesis that haemostatic therapy could reduce the volume of the haematoma and result in improved outcomes ([@b13]).

![Computerised tomography scan of haemorrhagic transformation](ijcp_873_f2){#fig2}

Diagnosis and Treatment of Acute Ischaemic Stroke
=================================================

Successful care of acute stroke patients relies on a four-step process: (i) prompt recognition and reaction to warning signs; (ii) immediate use of emergency services; (iii) priority transport with notification of the receiving hospital and (iv) rapid and accurate diagnosis and intervention at the hospital ([@b14], [@b15]). This 'chain of recovery' has also been described as a five-stage process, comprising the five Rs of successful stroke management: recognition (of symptoms), reaction (emergency services are called), response (medical assessment), reveal (brain imaging) and Rx (treatment initiation) ([@b16]).

Emergency Department Assessment
-------------------------------

Once a diagnosis of acute ischaemic stroke is suspected, the duration since symptom onset should be determined as accurately as possible, as time from onset is the single most important determinant of therapeutic options. Patients arriving at hospital with a symptom onset of \<3 h should be evaluated for potential treatment with rt-PA, although a 'door to needle time' of around 60 min usually means a hospital arrival time within 2 h for rt-PA candidates. A treatment algorithm is shown in [Fig. 3](#fig3){ref-type="fig"} ([@b2]).

![Algorithm for the management of acute stroke \[adapted with permission from Zweifler ([@b2])\]. BP, blood pressure, CEA, carotid endarterectomy, CT, computerised tomography; DVT, deep vein thrombosis; IA, intra-arterial; ICA, internal carotid artery; ICH, intracerebral haemorrhage, IV, intravenous; MRI, magnetic resonance imaging; NINDS, National Institute of Neurological Disorders and Stroke; NS, normal saline, rt-PA, recombinant tissue plasminogen activator; SAH, subarachnoid haemorrhage](ijcp_873_f3){#fig3}

Patients with acute stroke should be investigated with an emergency CT brain scan, to differentiate ischaemic stroke from ICH and other pathological processes such as subdural haematoma, tumour and abscess ([@b2]). Other emergency investigations should include blood glucose, electrolytes, full blood examination and an electrocardiogram.

Stroke Unit Management
----------------------

Rapid triage of patients to a stroke unit has been shown to reduce mortality by ≥20% ([@b17]) and improve functional outcomes ([@b18]), reducing disability and the need for institutional care compared with treatment in a general medical ward ([@b14]). A stroke unit is a geographically localised treatment facility involving a multidisciplinary stroke team of medical, nursing and allied health staff, incorporating best-practice stroke treatment protocols ([@b14], [@b19], [@b20]). Adherence to guidelines reduces costs with shorter hospital stays ([@b21]). However, access to stroke unit care remains a problem, even in countries with well-developed stroke systems ([@b22]--[@b25]).

Stroke units should use integrated care pathways, shown to reduce the risk of complications ([@b20]). An Australian study correlated improved outcomes in stroke units compared with general medical wards with adherence to processes of care ([@b26]). Stroke units can be supervised by a neurologist or a general physician with stroke training and expertise ([@b27], [@b28]).

Physiological monitoring is an important aspect of stroke unit management. Hyperglycaemia and fever should be avoided or treated vigorously, as they are independent adverse prognostic factors. Most stroke patients are hypertensive on admission, but blood pressure often spontaneously subsides. The management of acute hypertension is controversial, and randomised clinical trials are being performed to resolve this uncertainty ([@b29]).

Optimal management of acute stroke patients should include continuous respiratory and cardiac monitoring, fluid and metabolic replacement (usually intravenous normal saline), and treatment of hyperglycaemia, seizures and fever. Prophylaxis for complications such as deep vein thrombosis, pulmonary embolism, aspiration pneumonia and other infections are also essential ([@b2]). Antiembolic stockings should be routine, and low-dose heparin/heparinoid is widely recommended ([@b19]).

Antiplatelet therapy with aspirin is advised in ischaemic stroke unless there are contraindications or the patient is being treated with rt-PA ([@b15]). For every 1000 patients treated with acute aspirin, about nine deaths or nonfatal strokes are prevented ([@b30], [@b31]). Full anticoagulation is now rarely advocated for most patients in the acute stage, based on results from a series of negative trials ([@b32]). Heparin is frequently recommended for patients with cerebral vein thrombosis, arterial dissection and small infarcts, where there is a very high risk of recurrence. However, it should be emphasised that adequately powered randomised trials have not been performed for these indications.

Thrombolysis
------------

Randomised trials of intravenous rt-PA in acute ischaemic stroke ([@b33]--[@b38]) and subsequent meta-analyses ([@b32], [@b39], [@b40]) have demonstrated an overall benefit for rt-PA treatment, with a significantly increased probability of excellent recovery and no increase in mortality rate ([@b32]). Overall, the rate of symptomatic haemorrhagic transformation is increased threefold, but this is greatly outweighed by the therapeutic benefits.

Phase IV studies have subsequently established the relative safety of rt-PA in appropriate settings ([@b41]). The Canadian Alteplase for Stroke Effectiveness study ([@b42]) found that the rate of symptomatic ICH was low (4.6%) and that the 3-month outcomes were comparable with the National Institute of Neurological Disorders and Stroke (NINDS) study data ([@b42], [@b43]). Centres in Germany, the USA and Australia have published similar findings ([@b44]--[@b46]). Stroke guidelines therefore recommend the use of rt-PA in carefully selected patients within 3 h of the onset of ischaemic stroke ([@b14], [@b19]).

Optimal treatment outcomes with rt-PA are seen in specialist stroke centres. Failure to follow the NINDS guidelines and protocol violations ([@b9]) can lead to an increased risk of haemorrhage and a poorer patient prognosis ([@b47]). Hence, rapid referral of eligible patients to a specialist stroke centre should be facilitated ([@b48]), where there is expertise in neuroimaging, stroke evaluation and treatment in a co-ordinated stroke unit ([@b19]).

As mentioned previously, use of rt-PA remains disappointingly low in most countries. This reflects a number of factors, including not only the short time window, the relative lack of expertise and stroke emergency systems, and also professional pessimism. A vocal minority of emergency department physicians have argued that additional trial evidence is required ([@b41], [@b49]), but most experts, including European regulatory authorities, acknowledge that it is time to explore extended indications for rt-PA in stroke. For example, the European licensing approval of rt-PA for acute ischaemic stroke within 3 h of symptom onset after prior exclusion of intracranial haemorrhage stipulated that a randomised placebo-controlled trial of alteplase 3--4.5 h after symptom onset (ECASS III) be undertaken and that every treated patient must be entered onto a postmarketing registry (SITS-MOST). ECASS-III is a randomised trial to investigate the safety and efficacy of rt-PA when administered between 3 and 4 h after symptom onset ([@b50]).

Treatment of ICH
================

ICH is less common than ischaemic stroke (15 vs. 85% in most Western populations) but is associated with substantially worse outcomes. Mortality rates approach 50%, and there is little effective treatment. A recent trial of more than 1000 patients failed to demonstrate any benefit of early surgery for supratentorial ICH ([@b51]). In this trial, the overall mortality rate was 64%, and only about 25% of patients had a favourable outcome. The role of surgical evacuation is controversial, although there is a consensus for surgery in selected cases of cerebellar ICH.

The finding of haematoma growth in a significant proportion of patients with ICH led to the trials of the haemostatic agent rFVIIa. In a dose-ranging, proof-of-concept trial ([@b52]), haematoma growth was attenuated by nearly 50%. This was associated with a 40% reduction in mortality in the pooled rFVIIa-treated groups and improved functional outcomes. There was a small increase in myocardial and cerebral ischaemic events with rFVIIa, but this was substantially outweighed by the benefits. Based on these results, a second confirmatory trial is underway.

Optimal Practice and Drawbacks of Current Practices
===================================================

Failure to recognise the stroke symptoms is an important challenge. Up to 70% of patients having a stroke are unaware of it, because of lack of knowledge of symptoms or because they are asleep during onset ([@b53]). Furthermore, family members and/or carers do not always recognise the common signs of stroke, compounded by a lack of general awareness of the urgency of the condition. This underlies the need for public awareness campaigns to increase knowledge of stroke symptoms and facilitate patients being able to access urgent treatment.

Immediate ambulance transfer to a stroke centre should be facilitated ([@b14]). Accurate diagnosis remains a challenge in many settings, emphasising the importance of professional education. Rapid triage and prioritisation of stroke patients require the development of effective stroke-management systems ([@b14]).

Future Opportunities
====================

Despite these important advances in stroke treatment, it is clear that there is an urgent need for more widely applicable pharmacological therapy with a wider therapeutic window and an improved safety profile.

Reperfusion Approaches
----------------------

Beyond intravenous rt-PA, other reperfusion strategies in various stages of clinical trial evaluation include intra-arterial thrombolytic therapy, new thrombolytic agents such as desmoteplase, intravenous antiplatelet therapies such as abciximab, enhancement of thrombolysis with ultrasound and mechanical clot retrieval devices such as the recently licensed MERCI Retriever device ([@b54]) ([Table 1](#tbl1){ref-type="table"}). The benefits of reperfusion therapies always have to be balanced against the increased risk of bleeding complications. Ultrasound-enhanced thrombolysis was promising in one study ([@b55]) but associated with increased bleeding complications in another ([@b56]). An abciximab trial has been halted due to a high rate of bleeding complications.

###### 

Reperfusion strategies for the treatment of acute ischaemic stroke

  Strategy                           Agent                                     Comments
  ---------------------------------- ----------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  Antithrombotic agents              Heparin                                   Heparin is widely used in acute stroke, but no randomised clinical trials support its use
                                     Tinzaparin Low molecular weight heparin   Ongoing study of eptifibatide in combination with aspirin, tinzaparin and standard alteplase therapy
  Antiplatelet agents                Aspirin                                   Two trials showed a small (∼1%) but significant effect with early aspirin use in acute stroke ([@b30], [@b31])
                                     Abciximab                                 Ongoing Phase III studies
  Thrombolytics                      rt-PA                                     Approved
                                                                               Ongoing studies to investigate extension of treatment window to 6 h, intra-arterial administration and as combination therapy(e.g. with ultrasound)
                                     Pro-urokinase                             PROACT III trial planned
                                     Desmoteplase                              Dose-ranging Phase III trial planned
                                     Urokinase                                 MELT ongoing in Japan
  Mechanical clot retrieval device   MERCI Retriever                           Licensed
                                                                               In a study of 141 patients, efficacy appeared similar to that of rt-PA ([@b54])

rt-PA, recombinant tissue plasminogen activator; PROACT, prolyse in acute cerebral thromboembolism; MELT, MCA-Embolism Local fibrinolytic intervention Trial.

Ongoing clinical trials using rt-PA are aimed at prolonging the currently restrictive 3-h window. These include ECASS III (rt-PA vs. placebo 3--4 h after stroke onset) ([@b50]) and IST 3 (rt-PA vs. placebo 0--6 h after onset) ([@b57]). To date, there has only been one Phase III trial of intra-arterial thrombolysis. The Prolyse in Acute Cerebral Thromboembolism trial used a 6-h time window and focused on patients with middle cerebral artery (MCA)-territory infarction ([@b58]). The trial was positive, but a confirmatory trial is needed. Intra-arterial thrombolytic therapy is used in expert centres in highly selected patients, such as those with basilar artery thrombosis, where substantial Phase II evidence suggests a correlation between recanalisation and reduced mortality ([@b59]). However, one study indicated equally good results from intravenous thrombolytic therapy ([@b60]).

There are also several magnetic resonance imaging-based trials using combined perfusion-weighted imaging (PWI) and diffusion-weighted imaging (DWI), aimed at determining whether PWI \> DWI mismatch, as a signature of the ischaemic penumbra, can be used to select treatment responders beyond 3 h ([@b61]). Intravenous desmoteplase was shown to enhance reperfusion with associated clinical benefits up to 9 h in a recent study ([@b62]).

Neuroprotective Strategies
--------------------------

Ideally, acute therapy for ischaemic stroke would not require a preliminary CT scan so that therapy could potentially be administered by paramedical personnel in the prehospital setting. A safe therapy would also facilitate treatment outside of specialist stroke centres. An optimal neuroprotective strategy should be administrable intravenously, have a longer window of opportunity than rt-PA, be well tolerated and improve functional recovery after stroke. The proposed sites of action of various neuroprotective strategies within the ischaemic cascade are illustrated in [Fig. 4](#fig4){ref-type="fig"}.

![Schematic showing sites of action of neuroprotectants in the ischaemic cascade. AMPA, α-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid; GABA, γ-amino-butyric acid; NMDA, *N*-methyl-[d]{.smallcaps}-aspartate](ijcp_873_f4){#fig4}

To date, a large number of neuroprotective strategies have proved effective in animal models, but have generally failed translation to the clinical setting. However, the field has been revitalised with the positive results of the first trial of NXY-059 in acute ischemic stroke. Possible reasons for the many failed trials include difficulty with more complex and heterogeneous human stroke compared with the animal models, dosing issues with poor penetration of neuroprotective drugs into the ischaemic penumbra, relatively long therapeutic time windows used in many neuroprotective trials, adverse effects, inadequate sample size and other trial design issues. To improve the prospects of translational success, the Stroke Therapy Academic Industry Roundtable (STAIR) devised recommendations for clinical development of acute ischaemic stroke therapies. These criteria included human trials of agents that have been proven effective in more than one animal model, improved trial design with adequate sample sizes and valid outcome measures that are easy to measure, reproducible, valid, clinically meaningful and resistant to bias ([@b63], [@b64]).

Several novel neuroprotective compounds are currently in clinical development. These include NXY-059 (free-radical-trapping agent), DP-b99 (calcium chelator), magnesium (NMDA channel blocker) ([@b65]), ONO-2506 (astrocyte-modulating agent) ([@b66]), traxoprodil (NR2B-selective NMDA-receptor antagonist) ([@b67]) and citicoline (membrane stabiliser) ([@b68]).

Of these compounds, NXY-059 was the first to meet the STAIR criteria and is the most advanced in development ([@b69], [@b70]). NXY-059 is a novel free-radical-trapping neuroprotectant that limits infarct size and improves functional outcomes in animal models ([@b69]--[@b71]. Preclinical studies showed that NXY-059 reduces infarct size in both transient ([@b72], [@b73]) and permanent ([@b73], [@b74]) MCA occlusion (MCAO) stroke models in the rat. Furthermore, when administered 4 h after permanent MCAO in a primate model, NXY-059 produced improvements in motor paresis and spatial neglect ([@b75]).

NXY-059 has been shown to be well tolerated in stroke patients at doses that are neuroprotective in both transient and permanent MCAO models in animals ([@b76], [@b77]). A pharmacokinetic study of NXY-059 in acute stroke patients ([@b78]) showed that an initial loading dose, followed by a maintenance infusion (individualised by creatinine clearance), resulted in the early achievement of target plasma concentrations. NXY-059 is being evaluated in two Phase III Stroke Acute Ischaemic NXY-059 Treatment trials, one of which has been completed. The results of this trial of NXY-059 in 1699 patients showed that administration of this drug within 6 hours of the onset of ischemic stroke significantly improved the primary outcome, namely disability at 90 days. The drug also had an excellent safety profile. Although neurological functioning was not improved using a prespecified measure of change in the National Institutes of Health Stroke Scale (NIHSS), there were encouraging trends to benefit in the proportion of patients with excellent neurological recovery and in other outcome functional measures. In a further analysis, co-administration of NXY-059 and tPA was associated with a reduced rate of hemorrhagic transformation. A second pivotal trial of NXY-059 is well underway. Confirmation of the results of the initial trial should lead to availability of a treatment that could be widely applied and safely used alone or in patients co-treated with thrombolysis. These trial designs were based on the STAIR criteria ([@b64]). In addition, the Cerebral Hemorrhage and NXY Treatment (CHANT) trial is a double-blind, randomised trial aimed at assessing the safety and tolerability of intravenous infusion of NXY-059 in ICH.

ONO-2506 progressed to clinical development after demonstrating neuroprotective effects in rodent and primate models. ONO-2506 was shown to reduce infarct expansion in a rat model up to 48 h after permanent MCAO ([@b80]). When administered 6 h after permanent MCAO in a primate model (cynomolgus monkeys), ONO-2506 significantly reduced neurological symptoms up to 14 days after the onset of ischaemia ([@b81]). However, a Phase II study in the USA involving approximately 1300 patients was recently halted because of futility in an interim analysis ([@b82]). A Phase II/III study is currently ongoing in Japan.

Although intravenous magnesium sulphate was not effective within 12 h in a large Phase III trial ([@b83]), pilot studies in the USA have shown the feasibility of an ambulance-based therapy for stroke ([@b84]). A large Phase III trial is now underway with a 2-h time window, involving prehospital therapy (FAST-MAG) ([@b85]). There also remains a possibility that later administration of magnesium may be of benefit in lacunar stroke ([@b83]).

Conclusions
===========

Stroke is a clinical emergency requiring urgent medical intervention. Thrombolytic therapy with rt-PA is available for the treatment of acute ischaemic stroke, but its use is currently suboptimal. Recent advances in the organisation of acute stroke care, improved understanding of the evolving pathophysiology of both acute ischaemic stroke and ICH, together with advances in acute pharmacological therapy including neuroprotective approaches, are changing the way that acute stroke is managed around the world. Further advances in drug therapy are likely to occur in the next few years, with the potential for prehospital treatment of stroke patients. All of these treatment advances are based on immediate intervention, underlining the urgency of stroke recognition and treatment.
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